Peptide therapy TikTok claims: separating hype from evidence

What's this video probably claiming?

Based on the peptide category tag and the @justagrownwoman account, this video is almost certainly walking viewers through one or more of the heavy-hitter peptides circulating on wellness TikTok right now. BPC-157 and TB-500 are the usual suspects for injury recovery framing. CJC-1295 and ipamorelin get bundled together as a "growth hormone stack" with weight loss and anti-aging implications. GHK-Cu shows up in skin and collagen conversations. MK-677 gets sold as a safer alternative to injectable GH. The creator is probably speaking from personal experience, which is the engine that drives peptide content to 68K views. Expect anecdotal recovery stories, before-and-after framing, and confident dosing windows presented as established protocol. That confidence is the first thing worth interrogating.

What does the science actually show?

The honest answer is: a lot less than TikTok implies, and most of it in animals. BPC-157 has solid rodent data on tendon and gut healing. Seiwerth et al. (2014, Current Pharmaceutical Design) documented accelerated tendon-to-bone healing in rats at 10 mcg/kg doses, but no peer-reviewed randomized controlled trial in humans exists as of this writing. TB-500 (Thymosin Beta-4) has phase II trial data in cardiac patients (Goldstein et al., 2012, Annals of the New York Academy of Sciences), not in gym injuries. CJC-1295 increases IGF-1 and GH pulse amplitude in humans (Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism), but the subjects were healthy adults in a tightly controlled setting, not a population self-dosing from online vendors. MK-677, an oral GH secretagogue, raised GH levels in elderly patients (Nass et al., 2008, Annals of Internal Medicine) but also increased fasting glucose and insulin resistance, a detail that rarely makes it into the TikTok version.

Where does the social media noise diverge from clinical reality?

Several places, and they matter. First, purity and sourcing. Peptides sold for "research use only" are not subject to pharmaceutical manufacturing standards. A 2023 analysis published in JAMA Internal Medicine found significant label inaccuracies in compounded and research-grade peptides, including underdosing and contamination. Second, the CJC-1295 plus ipamorelin stack gets presented as interchangeable with pharmaceutical GHRH therapy. It is not. Third, MK-677 is frequently described as "not a steroid" and therefore safe for long-term use. The Nass 2008 data showed measurable increases in HbA1c after 24 weeks, which is a real metabolic signal, not a footnote. Fourth, GHK-Cu topical claims are extrapolated from in vitro fibroblast studies into systemic anti-aging claims that the data does not support at any injected or topical dose tested in humans.

What should you actually know?

Peptide therapy is a real clinical category with legitimate uses under physician supervision. The problem is the gap between supervised clinical use and the self-administered, vendor-sourced, TikTok-guided version of it. If you are considering any peptide protocol, the starting questions should be: Is this compounded by a licensed 503A or 503B pharmacy? Has a provider ordered labs to establish your baseline IGF-1, fasting glucose, and inflammatory markers? Do you have a diagnosis that actually corresponds to what this peptide has been studied for? The answer to all three is usually no when people come in after watching content like this. That does not mean the compounds are worthless. It means the context matters enormously, and context is exactly what a 60-second TikTok strips out.